FDA-cleared profile

BladderScan Prime PLUS System

Verathon Incorporated · Ultrasound · FDA-cleared (510(k))

Authorized purpose: BladderScan Prime PLUS is a diagnostic ultrasound system with a bladder indication for noninvasive measurement of urine volume in the bladder using the supported probe and device configuration.

Clinical role
Diagnostic ultrasound acquisition, measurement, analysis, and professional review support.
Images and patients
Ultrasound · Bladder
Key limitation
Keep in mind: Probe, mode, anatomy, population, acoustic window, workflow, and optional-feature limits vary by exact system and release.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: BladderScan Prime PLUS is a diagnostic ultrasound system with a bladder indication for noninvasive measurement of urine volume in the bladder using the supported probe and device configuration.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Bladder Input: Ultrasound acquisitions from supported probes, modes, presets, patient populations, and release-specific configurations.
  • Who uses it?Intended users: Qualified physicians, sonographers, and other appropriately trained ultrasound professionals.
  • What does the software produce?Output: Ultrasound image series, flow data, measurements, calculations, overlays, or reports for professional review.
  • What is its most important limitation?Key limitation: Probe, mode, anatomy, population, acoustic window, workflow, and optional-feature limits vary by exact system and release.

Clinical takeaway. Clinical role: BladderScan Prime PLUS is a diagnostic ultrasound system with a bladder indication for noninvasive measurement of urine volume in the bladder using the supported probe and device configuration.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical testing: the device was evaluated for electrical, thermal, mechanical and EMC safety, cleaning/disinfection, biocompatibility, and acoustic output and found to conform to applicable voluntary medical device safety standards, with design reviews, risk assessment, software verification and hardware verification. It states the device did not require clinical studies to support substantial equivalence. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
BladderScan Prime PLUS is a diagnostic ultrasound system with a bladder indication for noninvasive measurement of urine volume in the bladder using the supported probe and device configuration.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Diagnostic ultrasound acquisition, measurement, analysis, and professional review support.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Ultrasound acquisitions from supported probes, modes, presets, patient populations, and release-specific configurations.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Ultrasound image series, flow data, measurements, calculations, overlays, or reports for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospitals, clinics, point-of-care locations, offices, and procedural settings within the labeled applications.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified physicians, sonographers, and other appropriately trained ultrasound professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Probe, mode, anatomy, population, acoustic window, workflow, and optional-feature limits vary by exact system and release.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical testing: the device was evaluated for electrical, thermal, mechanical and EMC safety, cleaning/disinfection, biocompatibility, and acoustic output and found to conform to applicable voluntary medical device safety standards, with design reviews, risk assessment, software verification and hardware verification. It states the device did not require clinical studies to support substantial equivalence. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The BladderScan® PRIME PLUS system has been evaluated for electrical, thermal, mechanical and EMC safety. Additionally, cleaning/disinfection, biocompatibility, and acoustic output have been evaluated, and the device has been found to conform to applicable voluntary medical device safety standards." … "Assurance of quality was established by employing the following elements for product development: Design Reviews, Risk Assessment, Development of Requirements and Software Verification, Hardware Verification, and Safety Compliance Verification.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical testing: the device was evaluated for electrical, thermal, mechanical and EMC safety, cleaning/disinfection, biocompatibility, and acoustic output and found to conform to applicable voluntary medical device safety standards, with design reviews, risk assessment, software verification and hardware verification. It states the device did not require clinical studies to support substantial equivalence. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The BladderScan® PRIME PLUS system has been evaluated for electrical, thermal, mechanical and EMC safety. Additionally, cleaning/disinfection, biocompatibility, and acoustic output have been evaluated, and the device has been found to conform to applicable voluntary medical device safety standards." … "Assurance of quality was established by employing the following elements for product development: Design Reviews, Risk Assessment, Development of Requirements and Software Verification, Hardware Verification, and Safety Compliance Verification.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact submission-linked sensitivity endpoint with a verified population, threshold, tested version, and source was promoted.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact submission-linked specificity endpoint with a verified population, threshold, tested version, and source was promoted.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K172356 FDA evidence package for BladderScan Prime PLUS System

  • DesignFDA 510(k) decision evidence package reviewed for exact submission identity and labeled scope
  • PopulationLabeled population and configuration described in the K172356 FDA decision material
  • Scopeexact submission
  • Tested versionBladderScan Prime PLUS configuration described in K172356
  • IndependenceSponsor or vendor study

K172356

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
1 exact-submission FDA recall record matched K172356 in the 2026-09-02 openFDA snapshot. Confirm affected model, version, units, correction, and current manufacturer instructions locally. FDA recall Z-0531-2021 is Terminated for BladderScan Prime Plus Probe REF 0570-0395 - Product Usage: intended to be used for measuring the urine volume in the bladder noninvasively.. FDA reason: Due to a change in handle material and process, probe handle may crack. FDA action: On 10/5/2020, the firm sent a "Field Defect Correction URGENT MEDICAL DEVICE RECALL" Notification to its U.S, Customers via FedEx informing them that due to an unauthorized manufacturing change, the probe handle's plastic may become brittle and crack. Customer are instructed to: 1. Review the information contained within this Recall Notice with all staff members who should be aware of the contents of the letter. 2. Check the list of Serial Numbers that are provided within the Recall Response Form. 3. Perform a visual inspection of the probe handle for cracks or damage. 4. Based on the visual inspection of your device(s), please do one of the following: a. Unboxing and Initial Use " If your BladderScan Prime Plus probe handle plastics have no visible cracks or damage and / or you do not wish for units to be serviced, complete the attached Recall Response Form by indicating no or 0 in the text box and return the form to Verathon by email to CSNotifications@verathon.com. Or " If your BladderScan Prime Plus probe handle plastics have visible cracks and you wish for these units to be serviced, complete attached Recall Response Form by indicating by number the count of probe handle plastics that require repair in the text box and return the form by email to CSNotifications@verathon.com. Verathon Customer Care will contact you to arrange for repair of the probe handle plastics. This replacement will be at no charge to you. b. Subsequent Use If subsequent to submitting your Recall Response Form your BladderScan Prime Plus probes develop cracks (reference Figure 1) during subsequent use and you wish for them to be serviced, please email CSNotifications@verathon.com. Verathon Customer Care will contact you to arrange for repair of the probe handle plastics. This replacement will be at no charge to you. Follow the instructions within the BladderScan Prime Plus Operations and Maintenance Manual...
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-0531-2021

Terminated

2020-09-29

Native exact-submission identifier match from the openFDA candidate snapshot accessed 2026-09-04 with source snapshot date 2026-09-02. Source URL: https://api.fda.gov/device/recall.json?search=product_res_number.exact%3A%22Z-0531-2021%22&limit=1. This does not establish exact installed serial, lot, unit, or software-version applicability. The FDA record does not establish an AI-algorithm defect unless it says so.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Ultrasound acquisitions from supported probes, modes, presets, patient populations, and release-specific configurations.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K172356: BladderScan Prime PLUS System

  2. Routing

    Source context, not route validation: The exact FDA package describes the BladderScan PRIME PLUS system with USB and SD card data connections and an attached printer, each listed as identical to the predicate. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "Data Connections Identical to predicate USB, SD card" … "Attached Printer Identical to predicate Yes". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K172356: BladderScan Prime PLUS System

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Ultrasound image series, flow data, measurements, calculations, overlays, or reports for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K172356: BladderScan Prime PLUS System

  5. Viewer/worklist/report

    Unresolved route: Ultrasound image series, flow data, measurements, calculations, overlays, or reports for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K172356: BladderScan Prime PLUS System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact FDA package describes the BladderScan PRIME PLUS system with USB and SD card data connections and an attached printer, each listed as identical to the predicate. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Data Connections Identical to predicate USB, SD card" … "Attached Printer Identical to predicate Yes". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Training
Only qualified physicians, sonographers, and other appropriately trained ultrasound professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K172356 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Exact public integration details remain incomplete; establish and test the supported input, output, identity, routing, archive, report, and downtime contract locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the exact labeled population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Probe, mode, anatomy, population, acoustic window, workflow, and optional-feature limits vary by exact system and release.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. An exact-submission recall match exists; confirm affected model, version, units, correction, and completion status before acceptance.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K172356
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Bladder
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2017-09-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision and checked recall snapshot do not establish a complete local postmarket monitoring protocol. Track version, population, anatomy, protocol, input quality, edits, failures, repeats, downstream effects, downtime, incidents, recalls, and updates locally.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K172356: BladderScan Prime PLUS System

    U.S. Food and Drug Administration - Published 2017-09-15 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. BladderScan PRIME PLUS system model card (K172356)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. FDA recall Z-0531-2021: BladderScan Prime Plus Probe REF 0570-0395 - Product Usage: intended to be used for measuring the urine volume in the bladder noninvasively.

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  5. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  6. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  7. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  8. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K172356 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K232257

Clarius Bladder AI

Clarius Mobile Health Corp.

Authorized purpose: Provide semi-automatic, non-invasive bladder-volume measurements from ultrasound data acquired by the Clarius Ultrasound Scanner using curvilinear or phased-array scanners; a healthcare professional trained and qualified in ultrasound retains responsibility for the measurements, and the device is indicated for adults only.

Modality
Ultrasound
Anatomy
Bladder
Decision
2023-11-13
FDA-cleared K252237

EdgeFlow UW20

Edgecare, Inc.

Authorized purpose: EdgeFlow UW20 is a wearable ultrasound system for noninvasive periodic bladder-volume measurement in adults with BMI no greater than 30.

Modality
Ultrasound
Anatomy
Urinary bladder
Decision
2026-04-17

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history